Business
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two WeeksARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market. Kal
About this update from Block, Inc.
[{"type":"image","alt":"KALA BIO, Inc.","displaySize":"","headline":null,"caption":"KALA BIO, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":210,"url":"https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/poFKt69Bd.mweg6BAiQGYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46","width":300,"height":210}},"lazy":false},{"type":"text","content":"Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks","length":110,"tagName":"p"},{"type":"text","content":"ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market. Kala is building the Palantir for biotech, just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and pharmaceutical industry through its Researgency.ai platform, deploying purpose-built AI agents that handle the repetitive, high-stakes jobs that slow drug companies down, faster, cheaper, and with fewer errors than humans.","length":809,"tagName":"p"},{"type":"text","content":"THE PLATFORM IS LIVE. THE FIRST PRODUCT IS SHIPPING.","length":52,"tagName":"p"},{"type":"text","content":"With the full rebrand of Researgency.ai now complete, the platform is live and ready for enterprise clients. Kala’s scientists, working alongside Younet’s AI engineering team, are building the Company’s first custom AI agent right now, with delivery expected in approximately 14 days. This is not a rebranding announcement — this is a go-to-market readiness signal.","length":365,"tagName":"p"},{"type":"text","content":"“The rebrand was important, but the real story is what happens next, we launch,” said Avi Minkowitz, CEO of Kala. “We are building the Palantir for biotech. Our first agent ships in 14 days, and our team is fired up. This is the beginning of something big.”","length":257,"tagName":"p"},{"ty...